Drug Database
Back to search

Netherlands· NL-9acf8fb1e9e5

Zokinvy 50mg, harde capsules

A lonafarnib product containing lonafarnib, registered in Netherlands by TMC Pharma (EU) Limited. The same ATC class is registered in 12 of our 19 countries.

ATC A16AX20

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedZokinvy 50mg, harde capsulesATCA16AX20REGISTER NO.NL-9acf8fb1e9e5PACKS LISTED1CHECKEDSeptember 29, 2026
Compare price across countriesPer daily dose · free accountAsk the assistant about lonafarnibAnswers with sources · free accountCheck interactionsSeverity free · mechanism on Growth

Where it is registered

Lonafarnib is registered in 12 of 19 countries.

Countries holding a registration under ATC A16AX20 (lonafarnib), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 8 of them publish a price we can compare per daily dose
Search lonafarnib products by name

Lonafarnib · ATC A16AX20

12 / 19 countries

  • Belgiumprice
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Japan
  • Netherlands
  • Polandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

The record

At a glance

CBG-MEB (Netherlands)
Active substance
LONAFARNIB
Manufacturer
TMC Pharma (EU) Limited
Country
Netherlands (NL)
ATC code
A16AX20
ATC class
Lonafarnib
Defined daily dose
0.275 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1660

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

303 interactions on record for lonafarnib.

Graded by severity as the source publishes them — 153 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan
Check lonafarnib against other medicinesHow interaction checks work

Lonafarnib · interactions on record

303 records

  • 153 severe
  • 145 moderate
  • 5 minor

Most severe, free to view

  • ClotrimazoleA01AB18severe
  • CimetidineA02BA01severe
  • CisaprideA03FA02severe
  • AprepitantA04AD12severe
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Lonafarnib in 10 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All lonafarnib products

Authorised across Europe · EMA

The same active substance is authorised in 4 EEA countries. Names it is sold under:

  • France · Zokinvy
  • Iceland · Zokinvy
  • Liechtenstein · Zokinvy
  • Norway · Zokinvy

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/27ee076a-69eb-4c66-ab1f-0f699088259b
GET /v1/drugs/27ee076a-69eb-4c66-ab1f-0f699088259b?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Capsule, hard",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/zokinvy-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Lonafarnib",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126495",
  "excipients": [
    "AMMONIA (E 527)",
    "CROSCARMELLOSE  NATRIUM  (E 468)",
    "GELATINE (E 441)",
    "IJZEROXIDE GEEL (E 172)",
    "IJZEROXIDE ZWART (E 172)",
    "KALIUMHYDROXIDE (E 525)",
    "MAGNESIUMSTEARAAT (E 470b)",
    "POLOXAMEER 188",
    "POVIDON K 30 (E 1201)",
    "PROPYLEENGLYCOL (E 1520)",
    "SCHELLAK (E 904)",
    "SILICIUMDIOXIDE (E 551)",
    "TITAANDIOXIDE (E 171)",
    "ZWARTE INKT"
  ],
  "substances": [
    "LONAFARNIB"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/07/18",
  "procedure_number": "EMEA/H/C/005271",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1660",
  "additional_monitoring": "Y"
}
API referenceMCP serverPlans

See everything about lonafarnib.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.

Try it freeOpen in the console